High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma

by Chenglong Yue, Mingshan Niu, Qian Qian Shan, Ting Zhou, Yiming Tu, Peng Xie, Lei Hua, Rutong Yu, Xuejiao Liu
Published 2017-09-01

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

by Xuejiao Liu, Yulong Chong, Yiming Tu, Ning Liu, Chenglong Yue, Zhenglei Qi, Huize Liu, Yao Yao, Hongmei Liu, Shangfeng Gao, Mingshan Niu, Rutong Yu
Published 2016-10-01

Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway

by Xuejiao Liu, Yiming Tu, Yifeng Wang, Di Zhou, Yulong Chong, Lin Shi, Guanzheng Liu, Xu Zhang, Sijin Wu, Huan Li, Shangfeng Gao, Mingshan Niu, Rutong Yu
Published 2020-03-01

Prokineticin-2 prevents neuronal cell deaths in a model of traumatic brain injury

by Zhongyuan Bao, Yinlong Liu, Binglin Chen, Zong Miao, Yiming Tu, Chong Li, Honglu Chao, Yangfan Ye, Xiupeng Xu, Guangchi Sun, Pengzhan Zhao, Ning Liu, Yan Liu, Xiaoming Wang, Sin Man Lam, Valerian E. Kagan, Hülya Bayır, Jing Ji
Published 2021-07-01